Genmab achieves second pre-clinical milestone in Lundbeck collaboration

According to the collaboration, Genmab creates novel human antibodies to three targets identified by Lundbeck.

Lundbeck has access to Genmab’s antibody creation and development capabilities, including its fully automated pre-clinical antibody screening and characterization capabilities and its stabilized IgG4 and UniBody therapeutic antibody platforms.

As per the agreement, Genmab received an upfront payment of €7.5m in October 2010 (approximately DKK 56m).

Lundbeck fully funds the development of the antibodies.

Genmab CEO Jan van de Winkel said they have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration.